PL1608399T3 - Kompleks sklerostyny i nogginy lub chordyny, oraz czynniki modulujące tworzenie tego kompleksu - Google Patents

Kompleks sklerostyny i nogginy lub chordyny, oraz czynniki modulujące tworzenie tego kompleksu

Info

Publication number
PL1608399T3
PL1608399T3 PL04720380T PL04720380T PL1608399T3 PL 1608399 T3 PL1608399 T3 PL 1608399T3 PL 04720380 T PL04720380 T PL 04720380T PL 04720380 T PL04720380 T PL 04720380T PL 1608399 T3 PL1608399 T3 PL 1608399T3
Authority
PL
Poland
Prior art keywords
complex
sclerostin
chordin
noggin
tgf
Prior art date
Application number
PL04720380T
Other languages
English (en)
Inventor
David G Winkler
John Latham
John Skonier
Diana Shpektor
Trenton Hayes
James Geoghegan
Original Assignee
Ucb Mfg Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Mfg Inc filed Critical Ucb Mfg Inc
Publication of PL1608399T3 publication Critical patent/PL1608399T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
PL04720380T 2003-03-14 2004-03-12 Kompleks sklerostyny i nogginy lub chordyny, oraz czynniki modulujące tworzenie tego kompleksu PL1608399T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45525303P 2003-03-14 2003-03-14
PCT/US2004/007565 WO2004082608A2 (en) 2003-03-14 2004-03-12 Ligands for tgf-beta binding proteins and uses thereof
EP04720380A EP1608399B1 (en) 2003-03-14 2004-03-12 Complex of sclerostin and noggin or chordin, and agents that modulate the formation of said complex

Publications (1)

Publication Number Publication Date
PL1608399T3 true PL1608399T3 (pl) 2012-09-28

Family

ID=33029975

Family Applications (2)

Application Number Title Priority Date Filing Date
PL378566A PL378566A1 (pl) 2003-03-14 2004-03-12 Ligandy dla białek wiążących TGF-beta i ich zastosowania
PL04720380T PL1608399T3 (pl) 2003-03-14 2004-03-12 Kompleks sklerostyny i nogginy lub chordyny, oraz czynniki modulujące tworzenie tego kompleksu

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL378566A PL378566A1 (pl) 2003-03-14 2004-03-12 Ligandy dla białek wiążących TGF-beta i ich zastosowania

Country Status (15)

Country Link
US (1) US7226902B2 (pl)
EP (1) EP1608399B1 (pl)
JP (1) JP4660471B2 (pl)
AT (1) ATE540977T1 (pl)
AU (1) AU2004222317B2 (pl)
CA (1) CA2519131C (pl)
CY (1) CY1112797T1 (pl)
DK (1) DK1608399T3 (pl)
ES (1) ES2379689T3 (pl)
MX (1) MXPA05009805A (pl)
NZ (1) NZ542587A (pl)
PL (2) PL378566A1 (pl)
PT (1) PT1608399E (pl)
SI (1) SI1608399T1 (pl)
WO (1) WO2004082608A2 (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE481487T1 (de) 1998-11-27 2010-10-15 Ucb Sa Zusammensetzungen und verfahren zur erhöhung der knochenmineralisierung
CA2529623A1 (en) 2003-06-16 2005-02-17 Celltech R & D, Inc. Antibodies specific for sclerostin and methods for increasing bone mineralization
US8461155B2 (en) * 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
WO2007028212A1 (en) * 2005-09-08 2007-03-15 Apollo Life Sciences Limited Noggin and chimeric molecules thereof
EP2069558B1 (en) 2006-10-02 2013-05-01 Sea Lane Biotechnologies,llc. Design and construction of diverse synthetic peptide and polypeptide libraries
EP2460828A3 (en) * 2006-11-10 2012-08-08 UCB Pharma, S.A. Antibodies and diagnostics
EP2423226A3 (en) * 2006-11-10 2012-05-30 Amgen Inc. Antibody-based diagnostics and therapeutics
EP2114435A1 (en) * 2007-02-02 2009-11-11 Novartis AG Modulators of sclerostin binding partners for treating bone-related disorders
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
CN101896201A (zh) * 2007-12-14 2010-11-24 安进公司 使用抗硬骨素抗体治疗骨折的方法
JP6018753B2 (ja) * 2008-11-13 2016-11-02 ザ・ジェネラル・ホスピタル・コーポレイションＴｈｅ Ｇｅｎｅｒａｌ Ｈｏｓｐｉｔａｌ Ｃｏｒｐｏｒａｔｉｏｎ Ｂｍｐ−６の調節によって鉄の恒常性を制御するための方法および組成物
KR101163171B1 (ko) * 2009-01-20 2012-07-19 (주)케어젠 노긴?유래 펩타이드 및 그의 용도
SMT202000095T1 (it) 2010-05-14 2020-03-13 Amgen Inc Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
EA201391248A1 (ru) 2011-03-01 2014-05-30 Эмджен Инк. Биспецифические связывающие агенты
AP3981A (en) 2011-03-25 2017-01-05 Amgen Inc Anti - sclerostin antibody crystals and formulations thereof
SI2739311T1 (en) 2011-08-04 2018-07-31 Amgen Inc. Method for the treatment of bone defect defects
EP3712168A3 (en) 2011-12-28 2020-10-14 Amgen Inc. Method of treating alveolar bone loss through the use of anti-sclerostin antibodies
AU2013285488B2 (en) 2012-07-05 2018-03-22 Ucb Pharma S.A. Treatment for bone diseases
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
MA41142A (fr) 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
US10961305B2 (en) 2016-12-21 2021-03-30 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
EP3774879B1 (en) 2018-03-30 2026-01-28 Amgen Inc. C-terminal antibody variants

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846770A (en) * 1994-11-22 1998-12-08 Genetics Institute, Inc. DNA molecules encoding human chordin
CA2220912A1 (en) 1995-06-05 1996-12-12 Gregg A. Hastings Human ccn-like growth factor
US5989909A (en) 1997-09-26 1999-11-23 Millennium Biotherapeutics, Inc. Huchordin and uses thereof
US6117911A (en) * 1997-04-11 2000-09-12 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US6075007A (en) * 1997-07-17 2000-06-13 Regeneron Pharmaceuticals, Inc. Modified noggin polypeptide and compositions
ATE440143T1 (de) 1998-03-30 2009-09-15 Dow Agrosciences Llc Änderung der fettsäure-zusammensetzung in pflanzen durch expression einer aspergillus nidulans delta-9 coa desaturase
ATE481487T1 (de) 1998-11-27 2010-10-15 Ucb Sa Zusammensetzungen und verfahren zur erhöhung der knochenmineralisierung
JP2003525611A (ja) * 2000-03-02 2003-09-02 アムジェン インコーポレーテッド コルディン様−２分子およびその使用

Also Published As

Publication number Publication date
WO2004082608A2 (en) 2004-09-30
SI1608399T1 (sl) 2012-05-31
US20050085418A1 (en) 2005-04-21
MXPA05009805A (es) 2006-04-18
DK1608399T3 (da) 2012-04-02
ATE540977T1 (de) 2012-01-15
PT1608399E (pt) 2012-04-13
WO2004082608A9 (en) 2005-03-17
JP2006522103A (ja) 2006-09-28
EP1608399B1 (en) 2012-01-11
EP1608399A2 (en) 2005-12-28
AU2004222317A1 (en) 2004-09-30
JP4660471B2 (ja) 2011-03-30
ES2379689T3 (es) 2012-04-30
CA2519131A1 (en) 2004-09-30
NZ542587A (en) 2008-05-30
CA2519131C (en) 2014-07-08
AU2004222317B2 (en) 2010-08-19
PL378566A1 (pl) 2006-05-02
CY1112797T1 (el) 2016-02-10
WO2004082608A3 (en) 2005-01-20
US7226902B2 (en) 2007-06-05

Similar Documents

Publication Publication Date Title
PL1608399T3 (pl) Kompleks sklerostyny i nogginy lub chordyny, oraz czynniki modulujące tworzenie tego kompleksu
CY1124802T1 (el) Δεσμευτικοι παραγοντες σκληροστινης
MEP3108A (xx) Kompozicije i postupci za povećanje mineralizacije kostiju
MY174493A (en) Binding agents
WO2005014650A3 (en) Antibodies specific for sclerostin and methods for increasing bone mineralization
MX2007008017A (es) Polipeptidos que se ligan a br3 y usos de los mismos.
WO2006118772A3 (en) Fcrn antibodies and uses thereof
WO2008133722A3 (en) Anti human sclerostin antibodies
EA200702278A1 (ru) Антитела, специфичные в отношении tgf-бета 1
NO20090047L (no) Anti-DLL4-antistoffer og fremgangsmater for anvendelse av disse
WO2009067177A3 (en) Bone morphogenic protein binding peptide
MA28702B1 (fr) Composes et procedes pour l'inhibition de l'interaction de proteines bcl avec des partenaires de liaison
WO2005000207A3 (en) Pcdgf receptor antibodies and methods of use thereof
AR032548A1 (es) Metodo y composicion para desinfectar una superficie contaminada con una proteina prion
BRPI0507019A (pt) composição, uso de anticorpo, anticorpo, uso de msrv/herv-w env-su
ATE543833T1 (de) Bmp-7-varianten-zusammensetzungen, verfahren und verwendungen
TW200637830A (en) Erastin and erastin binding proteins, and uses thereof
WO2007100807A8 (en) Npc1l1 orthologues
WO2004070347A3 (en) Screening for modulators of fat storage
EP1496945A4 (en) POLYPEPTIDES OF MYCOPLASM
HK1151803B (en) Sclerostin binding agents
WO2006008266A3 (en) Factor xi-binding proteins
WO2007050554A3 (en) Methods for identifying compounds that modulate phb domain protein activity and compositions thereof
UA115859C2 (uk) Розчинний поліпептид, який зв'язує активін а, та композиція, що його містить
TW200718711A (en) Polypeptides that bind BR3 and uses thereof